Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06055920 · ClinicalTrials.gov registry record · NA
The PEERLESS II Study
A NA study of Pulmonary Embolism, sponsored by Inari Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT06055920: Recruiting NA study of Pulmonary Embolism, sponsored by Inari Medical.
NCT06055920 is a NA study of Pulmonary Embolism that is actively recruiting participants, run by Inari Medical. The registered enrollment target is 1,200 participants, below the 3,033-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06055920, a NA study of Pulmonary Embolism, is actively recruiting participants, sponsored by Inari Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Primary Outcome
* All-cause mortality by 30 days, or * Clinical deterioration, defined by hemodynamic or respiratory worsening, through discharge or up to 30 days after randomization, whichever is sooner, or * All-cause hospital re-admission by 30 days, or * Bailout therapy, either after a deterioration or after documented failure to progress, through discharge or up to 30 days after randomization, whichever is sooner, or * Change in Dyspnea, by mMRC from Baseline to the 48-hour visit
Conditions Studied
Interventions
- DEVICE FlowTriever System
- DRUG Anticoagulation Agents
Study Locations (20)
Alabama
- UAB Division of Cardiovascular Disease - Birmingham
- Brookwood Medical Center - Birmingham
Florida
- HCA FL Largo Medical Center - Largo
- AdventHealth Orlando - Orlando
Minnesota
- Metropolitan Heart & Vascular Institute - Coon Rapids
- Mayo Clinic - Rochester
Missouri
- Saint Luke's Hospital of Kansas City - Kansas City
- Mercy Hospital Springfield - Springfield
New Jersey
- Virtua Health - Camden
- Valley Health - Ridgewood
New York
- SUNY, The University of Buffalo/Gates Vascular - Buffalo
- Northwell Health - New York
California
- Huntington Memorial Hospital - Pasadena
Colorado
- University of Colorado, Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2023-11-17 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT06055920 shows while recruiting
NCT06055920 is an interventional study that assigns participants to a tested intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus, below the 3,033-participant average among 48 other Pulmonary Embolism trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Pulmonary Embolism appearing as the primary indexed condition, and to 2 interventions - of which FlowTriever System is the first listed.
NCT06055920 names 20 study sites across 14 states, led by Alabama, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06055920 about?
NCT06055920 is a clinical study titled "The PEERLESS II Study". This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
What is the current status of trial NCT06055920?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,200 participants. The study started on 2023-11-17. Estimated completion is 2026-07.
What conditions does trial NCT06055920 study?
This clinical trial studies the following conditions: Pulmonary Embolism.
What interventions are being tested in trial NCT06055920?
The interventions under investigation include: FlowTriever System (DEVICE), Anticoagulation Agents (DRUG).
Who is sponsoring clinical trial NCT06055920?
This trial is sponsored by Inari Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06055920 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Embolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06055920's enrollment target sits among peer trials
1,200 7th of 48 higher than 42 of 48 other Pulmonary Embolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Embolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU
RECRUITING · NA
-
The PERSEVERE Study
RECRUITING · NA
-
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
RECRUITING · NA
-
CLEANer Aspiration for Pulmonary Embolism
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI